Iterum Therapeutics plc
ITRMDelisted Jun 23, 2026- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001659323
Iterum Therapeutics plc was delisted on Jun 23, 2026; its insiders filed their last Form 4 on Nov 20, 2025; 18 institutions reported holding it in 13F filings for Q1 2026, worth $41.3K in total; no superinvestor held it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Iterum Therapeutics plc insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Iterum Therapeutics plc, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Dunne Michael W. | Director | 241,001 | Nov 20, 2025 | 1 |
| Coyne Christine | Chief Commercial Officer | – | Jul 3, 2025 | 0 |
| Hunt Ronald | Director | 91,122Indirect | Jan 23, 2025 | 0 |
| Fishman Corey N. | Chief Executive Officer | 137,062 | Aug 12, 2024 | 0 |
| Puttagunta Sailaja | Chief Medical Officer | 10,369 | Dec 4, 2023 | 0 |
| Hecht Beth | Director | 18,839 | Jun 15, 2023 | 0 |
| Chin Mark | Director | 18,306 | Jun 15, 2023 | 0 |
| Matthews Judith M. | Chief Financial Officer | 8,135 | Apr 3, 2023 | 0 |
| Ahrens Brenton Karl | Director | 0Indirect | Dec 28, 2022 | 0 |
| Kelly David George | Director | – | Jun 17, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 20, 2025 (view filing)7:00 AM ET | Nov 18 | 2 days | Dunne Michael W.Director | PPurchase | +6.00K | $0.3652 | +$2.19K | +2.6%241.0K after | |
| Aug 12, 2025 (view filing) | Aug 8 | 4 days | Dunne Michael W.Director | PPurchase | +15.0K | $0.72 | +$10.8K | +6.8%235.0K after | |
| Dec 27, 2023 (view filing) | Dec 22 | 5 days | Dunne Michael W.Director | PPurchase | +25.0K | $1.40 | +$35.0K | +28.2%113.8K after | |
| Dec 19, 2023 (view filing) | Dec 18 | 1 day | Dunne Michael W.Director | PPurchase | +10.0K | $1.84 | +$18.4K | +12.7%88.8K after | |
| Nov 27, 2023 (view filing) | Nov 22 | 5 days | Dunne Michael W.Director | PPurchase | +20.0K | $2.03 | +$40.6K | +34.0%78.8K after | |
| Nov 20, 2023 (view filing) | Nov 20 | Same day | Fishman Corey N.Chief Executive Officer | PPurchase | +10.0K | $1.59 | +$15.9K | +22.5%54.4K after | |
| Dec 5, 2022 (view filing) | Dec 2 | 3 days | Puttagunta SailajaChief Medical Officer | SSale | −3.37K | $1.32 | −$4.44K | −40.4%4.97K after | |
| Sep 20, 2022 (view filing) | Sep 16-20 | 4 days | Ahrens Brenton KarlDirector | SSale | −37.2K | $1.82 | −$67.9K | −100.0%0 after | 3 lots |
| Sep 15, 2022 (view filing) | Sep 13-15 | 2 days | Ahrens Brenton KarlDirector | SSale | −45.0K | $2.09 | −$93.9K | −54.7%37.2K after | 3 lots |
| Sep 12, 2022 (view filing) | Sep 8-12 | 4 days | Ahrens Brenton KarlDirector | SSale | −33.3K | $2.31 | −$76.9K | −28.8%82.2K after | 3 lots |
| Sep 9, 2022 (view filing) | Sep 7 | 2 days | Dunne Michael W.Director | PPurchase | +10.0K | $2.22 | +$22.2K | +39.1%35.6K after | From original |
| Mar 15, 2022 (view filing)7:12 PM ET | Mar 14 | 1 day | Matthews Judith M.Chief Financial Officer | SSale | −63.3K | $0.31 | −$19.6K | −49.2%65.3K after | Amended |